Whole Plasmid Sequencing Market to Reach USD 10.08 Billion by 2036 Amid Growing Gene Therapy Manufacturing

NEWARK, Del., USA | JUNE 04, 2026 - According to the latest analysis by Future Market Insights, the global Whole Plasmid Sequencing Market is witnessing strong growth, driven by expanding gene therapy and mRNA vaccine development pipelines, increasing regulatory requirements for complete plasmid characterization, growing demand for biopharmaceutical quality control, and rapid advancements in long-read sequencing technologies. As pharmaceutical and biotechnology companies intensify investments in advanced biologics, whole plasmid sequencing is becoming a critical component of vector validation, batch release testing, and manufacturing quality assurance, creating substantial opportunities for sequencing service providers and technology developers worldwide.

Featured Snippet: Key Market Insights

• Market Size (2025): USD 4.84 Billion

• Market Value (2026): USD 5.17 Billion

• Forecast Value (2036): USD 10.08 Billion

• CAGR (2026-2036): 6.9%

• Incremental Opportunity: USD 4.91 Billion

• Top Growth Markets: China and India

• Key Drivers: Growth in gene therapy manufacturing, increasing mRNA vaccine production, regulatory requirements for plasmid characterization, advancements in long-read sequencing technologies

• Leading Service Segment: Sequencing Services and Analysis

• Leading Application Segment: Gene Therapy Quality Control and Vector Verification

• Leading End User Segment: Biopharmaceutical Manufacturers and Hospitals

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-21436

Market Overview: Gene Therapy Expansion and Regulatory Compliance Drive Market Growth

The whole plasmid sequencing market is projected to grow from USD 5.17 billion in 2026 to approximately USD 10.08 billion by 2036, registering a CAGR of 6.9% during the forecast period.

Market expansion is being driven by increasing adoption of advanced biologics, rising commercialization of gene therapies, growing demand for plasmid DNA quality assurance, and the need for complete sequence verification to support regulatory submissions.

Sequencing workflows are rapidly evolving from research-focused applications toward validated, regulatory-compliant quality control processes that ensure vector integrity, eliminate sequence errors, and support product safety across pharmaceutical manufacturing operations.

Key Market Drivers

1. Rapid Growth in Gene Therapy and mRNA Vaccine Manufacturing

The increasing number of gene therapy programs and vaccine development initiatives continues to drive sequencing demand.

Key growth contributors include:

• Expansion of gene therapy clinical pipelines

• Rising demand for viral vector manufacturing

• Growth in mRNA vaccine production capacity

• Increased utilization of plasmid DNA in biologics development

Complete plasmid verification has become a critical requirement for ensuring therapeutic efficacy and regulatory compliance.

2. Regulatory Requirements for Comprehensive Vector Characterization

Global regulatory agencies continue strengthening quality requirements for biologic products.

This trend is supported by:

• Increased regulatory scrutiny of gene therapy products

• Requirements for complete plasmid sequence verification

• Enhanced quality control standards for biologics

• Growing emphasis on manufacturing consistency

These requirements are encouraging pharmaceutical companies to adopt comprehensive whole plasmid sequencing solutions.

3. Advancements in Long-Read Sequencing Technologies

Technological innovation is significantly improving sequencing efficiency and accuracy.

This trend is reinforced by:

• Improvements in nanopore sequencing platforms

• Adoption of single-molecule real-time sequencing technologies

• Reduction in sequencing costs

• Faster turnaround times for quality control testing

Advanced sequencing technologies are enabling complete plasmid characterization with greater confidence and operational efficiency.

👉 Speak to Analyst: Customize insights for your business strategy: https://www.futuremarketinsights.com/customization-available/rep-gb-21436

Segment Insights

Sequencing Services and Analysis Lead Market Demand

The sequencing services segment is expected to account for the largest share of market revenue in 2026 due to:

• Growing outsourcing by pharmaceutical companies

• Availability of validated workflows

• Faster turnaround capabilities

• Regulatory-compliant reporting services

Service providers continue benefiting from increasing demand for specialized plasmid characterization expertise.

Long-Read Sequencing Emerges as Preferred Technology

The long-read sequencing segment is projected to witness substantial adoption owing to:

• Single-pass complete plasmid sequencing

• Elimination of assembly artifacts

• Higher sequence confidence

• Improved detection of structural variations

Long-read technologies are increasingly becoming the preferred approach for pharmaceutical quality control applications.

Gene Therapy Quality Control Remains the Largest Application Area

Gene therapy manufacturing applications are expected to dominate market demand due to:

• Regulatory requirements for vector verification

• Increasing clinical-stage gene therapy programs

• Commercial manufacturing scale-up activities

• Recurring batch-release testing needs

Gene therapy developers continue to represent one of the most important customer groups for sequencing service providers.

👉 Explore the Latest Healthcare Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/healthcare

Regional Insights

China

China is projected to register the fastest growth with a CAGR of 18.4% through 2036, driven by:

• Rapid expansion of biopharmaceutical manufacturing

• Increasing gene therapy development activities

• Growing investment in advanced sequencing infrastructure

• Expansion of biologics production capacity

China continues strengthening its position as a major global biopharmaceutical manufacturing hub.

India

India is anticipated to expand at a CAGR of 17.0% owing to:

• Growth in pharmaceutical manufacturing

• Increasing biosimilar production activities

• Rising adoption of genomic quality control technologies

• Expansion of biotechnology research capabilities

India remains one of the fastest-growing markets for advanced sequencing services.

Germany

Germany is expected to grow at a CAGR of 15.7% due to:

• Advanced biopharmaceutical manufacturing infrastructure

• Strong regulatory compliance standards

• Leadership in pharmaceutical quality control

• Increasing biologics development activities

Germany continues to play a significant role in Europe's biotechnology ecosystem.

Brazil

Brazil is projected to grow at a CAGR of 14.3% through 2036, supported by:

• Expansion of pharmaceutical manufacturing capacity

• Growth in biologics production

• Increasing adoption of molecular quality control technologies

• Government support for biotechnology development

United States

The United States is expected to grow at a CAGR of 12.9% owing to:

• Leadership in gene therapy development

• Largest global biopharmaceutical market

• Established sequencing service infrastructure

• Strong regulatory and quality control requirements

The country continues leading innovation across advanced sequencing technologies.

United Kingdom

The United Kingdom is projected to grow at a CAGR of 11.6% through 2036, driven by:

• Strong biotechnology research ecosystem

• Expanding gene therapy development programs

• Regulatory emphasis on product quality

• Growing investment in genomic technologies

Japan

Japan is expected to grow at a CAGR of 10.2% due to:

• Advanced pharmaceutical manufacturing standards

• Precision quality control requirements

• Growing adoption of sequencing technologies

• Expansion of regenerative medicine programs

Technology and Research Trends

The whole plasmid sequencing market is evolving through advancements in:

• Nanopore-based sequencing technologies

• Single-molecule real-time sequencing platforms

• AI-assisted sequence analysis software

• Automated quality control workflows

• High-throughput plasmid characterization platforms

Manufacturers and service providers are increasingly focused on reducing turnaround times while improving sequencing accuracy and regulatory compliance.

👉 Get Full Report Access for Detailed Analysis: https://www.futuremarketinsights.com/reports/whole-plasmid-sequencing-market

Challenges in the Market

Cost and Throughput Constraints

The market continues facing challenges from:

• High sequencing costs for smaller organizations

• Throughput limitations for large-scale projects

• Requirement for specialized technical expertise

• Infrastructure investment requirements

Cost efficiency remains a key factor influencing adoption decisions.

Regulatory and Validation Complexities

Additional challenges include:

• Stringent validation requirements

• Evolving global regulatory frameworks

• Complex quality documentation standards

• Data integrity and compliance obligations

Service providers continue investing heavily in regulatory-compliant workflows and quality management systems.

Opportunities: Expansion of Advanced Biopharmaceutical Manufacturing

The market is unlocking new opportunities through:

• Growth of gene therapy commercialization

• Expansion of mRNA-based therapeutics

• Increasing biologics manufacturing activities

• Rising demand for outsourced sequencing services

• Adoption of precision medicine initiatives

Organizations capable of delivering rapid, accurate, and regulatory-compliant sequencing solutions are expected to strengthen their long-term market position.

Competitive Landscape

The whole plasmid sequencing market remains moderately competitive, with leading participants focusing on sequencing innovation, quality assurance capabilities, and pharmaceutical partnerships.

Leading Companies

• Thermo Fisher Scientific

• Eurofins Genomics

• Azenta Life Sciences

• Genewiz (Azenta)

• Plasmidsaurus Inc.

Emerging Companies

• Eton Bioscience

• Specialized Gene Therapy QC Service Providers

• Long-Read Sequencing Technology Developers

These organizations continue investing in technology upgrades, service expansion, and regulatory expertise to strengthen competitive positioning.

👉 Unlock high-growth opportunities with FMI's niche business market insights: https://www.futuremarketinsights.com/industry-analysis

Recent Developments

• In 2025, Thermo Fisher Scientific expanded its whole plasmid sequencing service capacity to support growing demand from gene therapy and vaccine manufacturers.

• In 2025, a leading sequencing provider launched a rapid-turnaround whole plasmid sequencing platform targeting batch-release testing and stability monitoring applications.

• Multiple biotechnology companies expanded long-read sequencing capabilities to improve plasmid characterization accuracy and reduce turnaround times.

Conclusion: Regulatory Compliance and Gene Therapy Growth to Sustain Long-Term Market Expansion

The whole plasmid sequencing market continues to evolve as biopharmaceutical manufacturers increasingly prioritize vector integrity, regulatory compliance, and manufacturing quality assurance. Expanding gene therapy pipelines, increasing biologics production, advancements in long-read sequencing technologies, and growing regulatory scrutiny are expected to support sustained market growth through 2036.

As advanced therapeutics become more prevalent globally, organizations with validated sequencing workflows, strong regulatory expertise, and scalable service capabilities are expected to lead the next phase of growth in the global whole plasmid sequencing industry.

* FAQs

1. How large is the whole plasmid sequencing market in 2026?
The global whole plasmid sequencing market is estimated at USD 5.17 billion in 2026.

2. What will be the whole plasmid sequencing market size by 2036?
The market is projected to reach USD 10.08 billion by 2036.

3. What growth rate is expected for the whole plasmid sequencing market?
The market is expected to grow at a CAGR of 6.9% from 2026 to 2036.

4. What is driving growth in the whole plasmid sequencing market?
Growth is being driven by expanding gene therapy manufacturing, increasing regulatory requirements, rising vaccine production, and advances in long-read sequencing technologies.

5. Which regions are expected to witness the fastest growth?
China and India are expected to be the fastest-growing markets through 2036.

* Have a Look at Related Research Reports on the Biotechnology Domain

· Platelet Rich Plasma Market - https://www.futuremarketinsights.com/reports/platelet-rich-plasma-market

· Specialty Control Plasma Market - https://www.futuremarketinsights.com/reports/specialty-control-plasma-market

· Radiopharmaceutical Market - https://www.futuremarketinsights.com/reports/radiopharmaceuticals-market

· Digital Pathology Market - https://www.futuremarketinsights.com/reports/global-digital-pathology-market

· Liver Fibrosis Treatment Market - https://www.futuremarketinsights.com/reports/liver-fibrosis-treatment-market

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com

Future Market Insights is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Newark, with a global delivery center in Pune and offices in the United Kingdom and United Arab Emirates, FMI delivers actionable insights across industries including food & beverage, healthcare, chemicals, and consumer goods.

An ESOMAR-certified organization, FMI provides data-driven insights to support strategic decision-making for global businesses.

This release was published on openPR.